Novacyt (LSE:NCYT) reported unaudited revenues of approximately £20.0m for 2025, slightly ahead of the £19.6m recorded in 2024 and broadly in line with market expectations. The group ended the year with a strong cash balance of £19.2m and no debt, providing financial flexibility as it continues to reshape the business.
Underlying revenue increased by around 4% year on year, or 5% at constant currency, despite the disposal of the Taiwan service laboratory. Clinical revenues rose 3% to £13.8m, supported by double-digit growth in non-invasive prenatal testing technologies. Instrumentation sales were a key growth driver, climbing more than 25% to £2.5m, while research-use-only revenues declined by roughly 10%, reflecting a shift in mix.
Regionally, APAC delivered the fastest growth at about 10%, driven mainly by reproductive health products. The group also achieved three consecutive half-year periods of revenue growth. Although Novacyt remains loss-making at the EBITDA level, management expects losses to at least meet, and potentially improve on, forecasts due to continued tight cost control.
On the commercial front, momentum is building around the new LightBench Discover long-read sequencing instrument, with 10 units placed since its launch in July 2025 and a growing sales pipeline. The company also expanded its research-use-only portfolio with the launch of the Primerdesign exsig Mag RapidBead Pro Extraction Kit, while beta testing progressed for Yourgene’s Insight DPYD assay in collaboration with international precision medicine specialists, ahead of a planned launch in the first half of 2026. Together, these initiatives underline management’s focus on stabilising the business and returning it to innovation-led growth.
More about Novacyt
Novacyt is an international molecular diagnostics company focused on genomic medicine. It develops, manufactures and commercialises molecular assays and instrumentation that deliver end-to-end workflows from sample to result. The group operates across clinical in vitro diagnostics, next-generation genomic instrumentation and research-use-only services, and sells into more than 65 countries. Novacyt is headquartered in France, with operations in the UK, Singapore, the US and Canada, and is listed on AIM in London and Euronext Growth in Paris.
Leave a Reply